Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
Passage Bio, Inc. (PASG)
Company Research
Source: GlobeNewswire
Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and seven global sites now activatedPursuing new indications for PBFT02, including adult neurodegenerative diseases FTD-C9orf72, amyotrophic lateral sclerosis (ALS) and Alzheimer’s diseaseEnded 2023 with robust balance sheet sufficient to deliver meaningful clinical data; with cash runway into Q4 2025 PHILADELPHIA, March 04, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided recent business highlights. "In 2023, we achieved a significant milestone by announcing encouraging data from three patients in Cohort 1 of our FTD-GRN program. This data showcased the ability of PBF
Show less
Read more
Impact Snapshot
Event Time:
PASG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PASG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PASG alerts
High impacting Passage Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PASG
News
- Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit [Yahoo! Finance]Yahoo! Finance
- Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewswire
- Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.MarketBeat
- Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program [Yahoo! Finance]Yahoo! Finance
PASG
Earnings
- 3/4/24 - Beat
PASG
Analyst Actions
- 3/5/24 - Canaccord Genuity
PASG
Sec Filings
- 4/17/24 - Form EFFECT
- 4/12/24 - Form SC
- 4/9/24 - Form DEFA14A
- PASG's page on the SEC website